A majority of Americans familiar with cannabidiol (CBD) say it should be available as an over-the-counter drug and believe that the compound has health benefits, according to a Gallup survey released June 14, 2019.
The CBD craze emerged from the marijuana reform movement and escalated following the passage of the 2018 Farm Bill, which federally legalized hemp and its derivatives including CBD. The survey, which involved 1,017 phone interviews conducted from May 15-30, offers some insight into the substance’s widespread appeal.
Thirty-nine percent of Americans overall said that people should be able to access CBD as an over-the-counter drug, with 21 percent saying a prescription should be required. Thirty-six percent of respondents said they weren’t familiar with the non-intoxicating compound.
But when Gallup asked people who said they were familiar with CBD the same question, 61 percent said that CBD should be sold over the counter and 33 percent said it should be available for those with a prescription.
Participants were also asked to rate their familiarity with CBD. Fourteen percent said they were very familiar, 33 percent said they were somewhat familiar, 17 percent said they were not too familiar, and 36 percent said they were not familiar at all.
Again, zeroing in on those who said they were familiar with CBD, Gallup asked what they thought about its therapeutic value.
Nine out of 10 respondents agreed that CBD does have health benefits. Breaking that down, 33 percent said it has a lot of benefits, 45 percent said it has some benefits and 14 percent said it has only a few benefits. Only four percent said it has no benefits and three percent didn’t have an opinion.
“The CBD-oil arena is extremely active right now, including medical research into its benefits, state legislation governing its sale, federal legislation encouraging its production and corporate investment growing in the business,” Gallup wrote. “Although medical research has a long way to go to investigate all of the claims made about CBD, half of Americans already believe it has at least some medical value, and that percentage is likely to grow as more become familiar with the product.”
The commercial interest in CBD is explosive, with lawmakers and industry stakeholders putting pressure on federal agencies such as the Food and Drug Administration (FDA) to streamline the regulatory process to provide for the compound’s lawful marketing in the food supply and as health supplements.
But even as the government develops those regulations, companies are wasting no time, flouting the FDA and putting CBD in drinks and foods such as pricey lattes and Carl’s Jr. burgers. At the same time, CBD’s medical value has been strongly established. The FDA approved a CBD drug, Epidiolex, in 2018 for the treatment of certain forms of epilepsy.
Gallup also released a separate survey June 13, 2019 that explored the various reasons Americans support or opposed broader marijuana legalization.
This article has been republished from Marijuana Moment under a content syndication agreement. Read the original article here.
Feature image by Christopher Burns